About Enzo
Enzo is a company based in Farmingdale (United States) founded in 1976 was acquired by Battery Ventures in June 2025. Enzo has raised $7 million across 1 funding round from investors including Battery Ventures. The company has 179 employees. Enzo has completed 2 acquisitions, including Asssay Designs and Biomol. Enzo offers products and services including AMPIVIEW® RNA Probes, Antibodies, and Immunoassays (ELISA). Enzo operates in a competitive market with competitors including Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others.
- Annual Revenue$32.64 M (USD)-72as on Jul 31, 2022
- Net Profit-$26.08 M (USD)-229as on Jul 31, 2024
- EBITDA-$11.76 M (USD)52as on Jul 31, 2024
- Total Equity Funding$7M (USD)
in 1 rounds
- Latest Funding Round$7M (USD), Series A
May 2023
- Investors
- Employee Count179
- Investments & AcquisitionsAsssay Designs
& 1 more
- Acquired byBattery Ventures
(Jun 2025)
Products & Services of Enzo
Enzo offers a comprehensive portfolio of products and services, including AMPIVIEW® RNA Probes, Antibodies, and Immunoassays (ELISA).
Tools for RNA detection in cells and tissues via in situ hybridization.
Reagents for detecting specific proteins in research applications.
Kits for accurate detection of small and large analytes.
Funding Insights of Enzo
Enzo has successfully raised a total of $7M through 1 strategic funding round. The most recent funding activity was a Series A round of $7 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7M
- Total Rounds 1
- Last Round Series A — $7M
- First Round $7M
(May 2023)
All 1 funding rounds of Enzo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $7M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Enzo
Enzo has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Battery Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in technology companies are conducted globally by Battery Ventures. | – | battery.com | - |
Investor details for Enzo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enzo
20 people are tracked at Enzo (4 in leadership, 4 in board & advisors, 12 in team); the tracked headcount is 179.
| Name | Role | Group |
|---|---|---|
Kara Cannon | Corporate VP, Commercial Operations | Leadership |
Patricia Eckert | Interim CFO | Leadership |
Hamid Erfanian | CEO | Leadership |
Craig Chin | Assistant Director Of Operations | Leadership |
Elazar Rabbani | Chairman | Board & advisors |
Mary Tagliaferri | Director | Board & advisors |
Ian Walters | Director | Board & advisors |
Bradley Radoff | Director | Board & advisors |
Matthew Kupferberg | General Counsel | Team |
Jens Bauer | Strategischer Account-manager | Team |
Margaret B. | Senior Manager Customer Service | Team |
Anaïs Goussin | Senior Sales Manager, EMEA & APAC | Team |
Gelda Veliu | Senior Commercial Operations Analyst | Team |
Alexandros Spinthakis | Logistics Manager | Team |
Jaspal Kaur | Associate Manager | Team |
Karin Ammann | Distribution Manager | Team |
Serges Pouedet | Senior Strategic AM | Team |
Rebecca Jane Walker | Junior Controller | Team |
Lauren Howard | Regional Account Manager | Team |
Hiromi Klute | Senior Key Account Manager | Team |
Complete people profiles for Enzo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enzo
Enzo has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Asssay Designs and Biomol.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Design services are provided by Asssay Designs in Ann Arbor. | asssaydesigns.com | Ann Arbor, United States | 0 | Mar 2009 | $12.2M | |
Online marketplace for reagents, antibodies, and assays is provided. | biomol.com | Hamburg, Germany | 1968 | May 2008 | $18M |
Complete acquisition details for Enzo
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Enzo
6 dated milestones of Enzo across 49 years, from founding to its latest funding, stage changes and deals.
- Founded Enzo is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Biomol.
- Acquisition Acquires Asssay Designs.
- Funding First funding round of $7.0M.
- Exit Acquired by Battery Ventures.
Competitors of Enzo
Enzo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| bbisolutions.com | 1986 | Crumlin, United Kingdom | – | 301 | Kits and reagents are developed for life science research applications. |
Detailed competitors of Enzo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enzo
The website of Enzo (enzo.com) receives about 127.6K visits a month and ranks #344,558 among all websites worldwide, #12,222 in Biotechnology and Pharmaceuticals.
- Monthly visits127.6K
- Unique visitors55.4K
per month
- Global rank#344,558
among all websites
- Category rank#12,222
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.7
- Average visit32 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Enzo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| myriad.com | 100% | 205.3K | #109,684 | View details | |
| enzon.com | 91% | 1.4K | #8,914,161 | View details | |
| progenics.com | 82% | – | – | View details | |
| genzyme.com | 81% | – | – | View details | |
| mercodia.com | 78% | 3.6K | #3,052,717 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Enzo
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Enzo
Complete news archive for Enzo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Enzo
10 companies that operate in the same segment as Enzo (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Enzo
Enzo was founded in 1976 and raised its 1st funding round 47 years after it was founded.
Enzo is headquartered in Farmingdale, United States. It is registered at Farmingdale, New York, United States.
Enzo is a funded company, having raised a total of $7M across 1 funding round to date. The company's 1st funding round was a Series A of $7M, raised on May 2023.
Enzo has 179 employees.
Annual revenue of Enzo is $32.64M as on Jul 31, 2022.
Enzo Biochem is developing therapeutics, diagnostics, and reagents through its subsidiaries. It is developing therapeutic products through Enzo Therapeutics and focused on gastroenterology, ophthalmology, metabolic and bone disorders and infectious diseases. It has developed technology platforms such as Immune Regulation, gene technology and cell signaling modulation to develop various drugs. It has developed a gene delivery vehicle, the StealthVector. Through its cell signaling platform, it has discovered small molecules to treat cancer and skin disoreders.
Enzo's top competitors include Abcam, Sino Biological and Meridian Bioscience.
Enzo offers AMPIVIEW® RNA Probes, Antibodies, and Immunoassays (ELISA).
Enzo has made 2 acquisitions, including Asssay Designs, and Biomol.
Enzo has 1 investor. Key investors include Battery Ventures.
Enzo operates through Enzo Biochem Inc.
Yes. Enzo was acquired by Battery Ventures in June 2025.